* Q1 EPS C$0.40 vs C$0.16 last year
* Rev up 3 pct
* Forecast 2011 rev up 2-6 pct (Follows alerts)
May 25 (Reuters) - Canadian specialty pharmaceuticals company Paladin Labs Inc’s quarterly profit more than doubled, partly helped by promotions of certain drugs.
Paladin forecast 2011 revenue to rise 2-6 percent to C$130-C$135 million.
January-March profit rose to C$8.1 million, or 40 Canadian cents a share, from C$3.1 million, or 16 Canadian cents a share a year ago.
Revenue rose 3 percent to C$31.7 million.
The company benefited from the marketing of pain drug Tridural, analgesic Metadol, testosterone gel Testim and contraceptive Plan B.
Shares of the company closed at C$44.05 on Wednesday on the Toronto Stock Exchange. (Reporting by Aftab Ahmed in Bangalore; Editing by Joyjeet Das)